BioBricks Co., Ltd. is a biotechnology company developing regenerative biomaterials and medical devices based on tissue-derived decellularized extracellular matrix (dECM) technology. Our proprietary manufacturing platform preserves the tissue-specific bioactive components and microenvironment of native extracellular matrices, enabling the development of advanced solutions that support tissue repair and regeneration.

Our product pipeline includes OrganINK®, a research-use dECM bioink; GelCODE®, a corneal tissue adhesive; GelMUDE, a biomaterial for periodontal tissue regeneration; and dECM-based materials for tissue regeneration and aesthetic applications. Through these innovative products, BioBricks aims to provide next-generation regenerative solutions for researchers, healthcare professionals, and patients.

By combining biomaterial engineering, tissue-specific dECM technology, and product development expertise, BioBricks is committed to improving treatment options and enhancing quality of life for people with damaged or compromised tissues.